RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2008; 99(04): 653-654
DOI: 10.1160/TH08-02-0120
DOI: 10.1160/TH08-02-0120
Editorial Focus
Factor VIIa gets even bigger
Autoren
Weitere Informationen
Publikationsverlauf
Received: 28. Februar 2008
Accepted after major revision: 28. Februar 2008
Publikationsdatum:
25. November 2017 (online)
-
References
- 1 Lindley CM, Sawyer WT, Macik BG. et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-648.
- 2 Bysted BV, Scharling B, Moller T. et al. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 2007; 13: 527-532.
- 3 van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-1335.
- 4 Hoffman M, Monroe DM. 3rd. The action of highdose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis Mon 2003; 49: 14-21.
- 5 Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
- 6 Goodnough LT, Shander AS. Recombinant factor VIIa: safety and efficacy. Curr Opin Hematol 2007; 14: 504-509.
- 7 Weimer T, Wormsbächer W, Kronthaler U. et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659-667.
- 8 Yeh P, Landais D, Lemaitre M. et al. Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate. 1992; 89: 1904-1908.
- 9 Syed S, Schuyler PD, Kulczycky M. et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 1997; 89: 3243-3252.
- 10 Melder RJ, Osborn BL, Riccobene T. et al. Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice. Cancer Immunol Immunother 2005; 54: 535-547.
- 11 Wang W, Ou Y, Shi Y. AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. Pharm Res 2004; 21: 2105-2111.
- 12 Subramanian GM, Fiscella M, Lamouse-Smith A. et al. Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 2007; 25: 1411-1419.
- 13 Kim J, Bronson CL, Hayton WL. et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol 2006; 290: G352-360.
- 14 Sheffield WP, Mamdani A, Hortelano G. et al. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 2004; 126: 565-573.
- 15 Gui T, Lin HF, Jin DY. et al. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo. Blood 2002; 100: 153-158.
- 16 Ghosh S, Pendurthi UR, Steinoe A. et al. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 2007; 282: 11849-11857.
- 17 Bayer RJ, Ostergaard H, Kalo MS. et al. Development of long-acting fVIIa derivatives by glycopegylation ™. J Thromb Haemost 2007; 5 (Suppl) P-T-016.